Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02361190 · ClinicalTrials.gov registry record · NA
Effects of Fast Acting Testosterone Nasal Spray on Anxiety
A NA study, sponsored by University of Texas at Austin.
- Completed
- Registry status
- NA
- Development phase
- 96
- Enrollment target
NCT02361190: Completed NA study, sponsored by University of Texas at Austin.
NCT02361190 is a NA study that has completed, run by University of Texas at Austin. The registered enrollment target is 96 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02361190, a NA study, has completed, sponsored by University of Texas at Austin.
- COMPLETED
- Registry status
- NA
- Development phase
- 96 participants
- Enrollment target
Study Summary
The proposed study will test the effects of a fast-acting testosterone nasal spray on the fear reactions of young men to two distinct anxiety challenges (social and nonsocial) using a double-blind randomized experimental design.
Primary Outcome
Subjects will be asked to approach a fearful object. Approach will be measured as number of steps (out of 18) the subject completes, with each step bringing the subject closer to the target object
Interventions
- DRUG Placebo
- DRUG Testosterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-05 |
| Phase | NA |
What the finished NCT02361190 record still lists
NCT02361190 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02361190 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02361190 about?
NCT02361190 is a clinical study titled "Effects of Fast Acting Testosterone Nasal Spray on Anxiety". The proposed study will test the effects of a fast-acting testosterone nasal spray on the fear reactions of young men to two distinct anxiety challenges (social and nonsocial) using a double-blind randomized experimental design.
What is the current status of trial NCT02361190?
This trial is currently completed. It is a NA study. The enrollment target is 96 participants. The study started on 2015-02. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02361190?
The interventions under investigation include: Placebo (DRUG), Testosterone (DRUG).
Who is sponsoring clinical trial NCT02361190?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02361190's enrollment target sits among peer trials
96 925th of 2000 higher than 1,070 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia